
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
CMS will not appeal preliminary injunction against average manufacturer price rule.
The Centers for Medicare & Medicaid Services has decided not to appeal a preliminary injunction that has blocked it from implementing the






